• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Antibodies attacking cancer cell
Cancer

DS-3939a ADC for treating TA-MUC1-expressing tumors

July 16, 2025
No Comments
Antibody-drug conjugates (ADCs) are therapeutics that combine an antibody with a cytotoxic payload via a chemical linker to specifically target certain cells. Tumor-associated mucin-1 (TA-MUC1) is a glycosylated form of the MUC1 protein that is expressed in several cancer cells, thus being an interesting target for ADC development.
Read More
Endocrine/metabolic

RT-114 robotic capsule matches injectable PG-102 in preclinical study

July 16, 2025
No Comments
Incretin-based therapies have demonstrated substantial efficacy in the treatment of metabolic diseases such as obesity and type 2 diabetes but the need for frequent injections remains a major barrier to patient adherence and comfort.
Read More
Optogenetics illustration
Ocular

Aavantgarde Bio cleared to begin clinical study of Stargardt disease gene therapy in US

July 16, 2025
No Comments
The U.S. FDA has cleared Aavantgarde Bio Srl’s IND application for AAVB-039, the company’s gene therapy program for Stargardt disease, the most common inherited form of macular degeneration.
Read More
Elderly woman holding illustration of brain with missing puzzle piece
Neurology/psychiatric

Acumen and JCR enter collaboration to develop BBB-penetrating Alzheimer’s treatment

July 16, 2025
No Comments
Acumen Pharmaceuticals Inc. and JCR Pharmaceuticals Co. Ltd. have entered a collaboration, option and license agreement to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD).
Read More
Doctor measuring patient's waist
Endocrine/metabolic

Palatin Technologies reports efficacy of PL-7737 in obesity model

July 16, 2025
No Comments
Palatin Technologies Inc. has announced preclinical results for PL-7737, an oral selective melanocortin MC4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity.
Read More
Transmission electron micrograph of HIV-1 virus particles
HIV/AIDS

IAS 2025: All eyes still on the HIV reservoir

July 16, 2025
By Mar de Miguel
No Comments
While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent state within cellular reservoirs that scientists do not know how to eliminate. “Transcription is a critical step in the viral life cycle. … But there are currently no drugs suppressing HIV transcription, and that may be one of the reasons why current antiretroviral therapy is not curative,” Melanie Ott told the audience at the 13th IAS Conference on HIV Science this week in Kigali, Rwanda.
Read More
Neurology/psychiatric

Pfizer describes new STAT6 inhibitors

July 15, 2025
Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, atherosclerosis, metabolic dysfunction-associated steatohepatitis, respiratory and dermatological disorders.
Read More
Cancer

AGC presents new EP4 antagonists

July 15, 2025
AGC Inc. has synthesized compounds acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of cancer.
Read More
Neurology/psychiatric

2A Biosciences discovers 5-HT2A receptor agonists

July 15, 2025
2A Biosciences Inc. has described phenethylamines acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.
Read More
Cancer

Arrakis Therapeutics patents new c-Myc inhibitors

July 15, 2025
Arrakis Therapeutics Inc. has disclosed Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 17793 17794 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 23, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe